

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **VOLUNTARY ANNOUNCEMENT UPDATES ON THE CLINICAL TRIAL OF IMM47**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that the Group has obtained an investigational new drug (IND) approval for IMM47 for the treatment of solid tumors from the National Medical Products Administration of the People's Republic of China (NMPA).

### **ABOUT IMM47**

IMM47 is a potentially global first-in-class humanized monoclonal antibody targeting CD24 for cancer treatment. With a high affinity for CD24 expressed on tumor cells, IMM47 can suppress the immune inhibitory signals sent from CD24/Siglec-10 pathway to macrophages, natural killer (NK) cells and T cells. With the antibody-dependent cellular cytotoxicity (ADCC)-enhanced IgG1 Fc, IMM47 can potently activate macrophage and NK cell-immune responses through strong antibody-dependent cellular phagocytosis (ADCP) and ADCC. The Company's *in vivo* proof-of-concept studies have demonstrated that IMM47 can significantly increase the amount of M1 macrophages in tumor tissues, it has the promising efficacy, and it can also create a strong synergistic potential with other immunotherapies, such as programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors.

On September 26, 2023, the Group dosed the first patient for the Phase I clinical trial of IMM47 in Australia. On September 9, 2023, the preclinical results of IMM47 were published on *Antibody Therapeutics*, a peer-reviewed journal, which provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community.

As of the date of this announcement, with respect to IMM47, the Group owned one issued patent in China, one allowed patent application in Japan, one pending patent application in each of the United States and the European Union, and one pending Patent Cooperation Treaty (PCT) patent application that may enter various contracting states in the future. Furthermore, the IND application for IMM47 for the treatment of solid tumors with the Food and Drug Administration of the United States (FDA) is expected to be filed in the near future.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM47, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術(上海)股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Hong Kong, October 16, 2023

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Song Ziyi as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*